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Abstract
Objective—Given the emerging appreciation for the role of antibody-dependent effector 
functions and IgG subclass distribution among spontaneous controllers of HIV, we sought to 
determine whether antibody-associated features diverged in early HIV infection between subjects 
who ultimately became controllers versus those who became progressors.
Methods—IgG was purified from plasma from nine acutely infected subjects who subsequently 
controlled HIV spontaneously (controllers) and ten acutely infected individuals who did not 
control viremia (progressors). Antibody profiles were compared at weeks 4, 12, 24 and 48 post-
infection. Levels of clade B gp120-, gp140-and gp41-specific IgG antibody subclasses were 
measured. Additionally, gp120-specific antibody-dependent cellular phagocytosis (ADCP), rapid 
fluorescent antibody-dependent cellular cytotoxicity (RFADCC), and antibody-dependent cellular 
viral inhibition (ADCVI) were all assessed.
Results—While no single Ab-related measurement was significantly associated with long-term 
HIV control, combinations of Ab-associated variables were able to accurately differentiate 
controllers and progressors. In contrast to controllers, progressors showed greater dynamic 
changes in gp120-specific subclass selection profiles, with increasing levels of Env-specific IgG2 
Abs and losses in Env-specific IgG3 Abs. Moreover, progressors, but not controllers, lost ADCVI 
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function over time. Together, these results highlight changes in IgG subclass selection profiles in 
progressive, but not controlled, HIV infection.
Conclusions—This study suggests that the temporal variation and maintenance of Env-specific 
IgG subclasses during acute HIV infection are predictive of eventual disease control. The 
maintenance of gp120-specific and gp140-specific IgG3 may contribute to control of disease in 
spontaneous controllers. Thus, strategies to induce stable IgG3 responses may preserve control of 
the viral reservoir.
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Introduction
While neutralizing antibodies (Abs) have been considered the gold standard for protection 
against HIV infection, they take months to naturally develop and therefore are unlikely to 
contribute to initial control of disease[1]. In both human and animal models of HIV infection, 
there is accumulating evidence to support a role for non-neutralizing Abs in the control of 
disease progression[2–6] and possibly in protection from initial infection[7–10]. These Abs are 
capable of eliciting complement activation and activating FcγR-expressing cells, such as 
macrophages and natural killer (NK) cells, via their Fc domains; however, not all Abs are 
equivalently potent at inducing Fc-dependent functions. Among the IgG subclasses, IgG3 
and IgG1 exhibit much higher affinities for FcγRs as compared to IgG2 and IgG4[11] and 
are therefore superior at inducing several Ab-dependent effector functions, including 
complement activation, Ab-dependent cellular viral inhibition (ADCVI) and Ab-dependent 
cellular cytotoxicity (ADCC). While IgG2 plays a critical role in controlling bacterial 
infections and IgG4 may negatively modulate immune responses, in the context of HIV 
infection, Env-specific IgG2 may inhibit internalization of opsonized HIV[12]. In contrast, 
disease progression is associated with a decline in both ADCVI and ADCC[13] that is 
concomitant with HIV-specific IgG3 Ab decay following acute infection[13, 14]. Moreover, in 
non-human primate (NHP) and human cohort studies both ADCVI and ADCC have been 
shown to inversely correlate with viremia[15–17].
Among HIV infected individuals, a small population of HIV infected individuals are able to 
spontaneously control HIV and are known as “controllers”[18]. Viral control has been 
attributed to an enrichment of protective HLA Class I alleles in some controller cohorts[19], 
but other studies have also suggested that non-neutralizing Ab functions may contribute to 
suppressing viremia in an non-HLA dependent manner[20–24]. Previous studies point to a 
selective enrichment of polyfunctional humoral responses, along with IgG3 and IgG1 Abs, 
in controllers as compared to chronic progressors[25, 26]. However, whether these responses 
emerge early in infection to directly control the virus or virally infected cells or simply 
emerge later in disease as a biomarker of a more well controlled immune response is 
unknown. Additionally, whether controllers maintain more polyfunctional antiviral HIV-
specific IgG3 responses during acute infection is uncertain, but the existence of such 
responses could point to a critical role for antibodies in early control of viral replication. In 
Sadanand et al. Page 2
AIDS. Author manuscript; available in PMC 2019 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
this study, we measured Ab-dependent features, including HIV-specific IgG subclass titers 
and several Ab-dependent effector functions, in a unique cohort of acutely infected subjects 
tracked in the first year post-infection, and later found to either spontaneously control 
disease (controllers) or become chronically infected (progressors). We show that temporal 
variation of IgG3 and IgG2 is a predictor of disease progression in acute-infected HIV 
subjects.
Methods
Cohort Samples
Subjects were recruited as part of the San Diego Acute and Early Infectious Disease 
Research Program and all subjects signed informed consents to protocols approved by the 
University of California San Diego Human Subjects Committee. Plasma samples were 
collected from 10 acutely infected chronic subjects (progressors) and 9 spontaneous 
controllers at 4, 12, 24 and 48 weeks after the estimated date of infection[27].
Controllers and progressors were defined using previously established criteria[28]. 
Specifically, controllers included individuals who maintained viral loads at or below 3000 
copies/ml for at least 3 visits over the first year of infection in the absence of antiretroviral 
therapy. Median plasma viral loads for controllers were 392 (week 4), 206 (week 12), 558 
(week 24) and 733 (week 48). Median plasma viral loads for progressors were 319,182 
(week 4), 133,000 (week 12), 106,000 (week 24) and 80,950 (week 48). Controllers had 
significantly lower median plasma viral loads at all 4 time points.
IgG was purified from plasma samples using Melon Gel (Thermo Scientific). Total IgG 
concentration was calculated by Human IgG ELISA kit (MABTECH). All assays were 
repeated in triplicate.
gp120 binding titers
Ninety-six-well ELISA plates (Nunc) were coated overnight at 4°C with recombinant 
gp120MN (rgp120MN; Immune Technology). HIV-IG (NIH AIDS Reagents) was used as a 
positive control. Peroxidase-conjugated anti-human IgG (R&D Systems) was used as a 
secondary antibody and developed by addition of O-phenyl-enediamine. Reactions were 
stopped with H2SO4, and the optical density was read at 492 and 605 nm.
Luminex Isotype Assay
A luminex isotype assay was used to quantify the relative concentration of each isotype/
subclass among the HIV-specific Abs as previously described[29]. Luminex microspheres 
carboxylated beads (Luminex) were coupled to rgp120MN, rgp140 clade B and rgp41 
(Hxbc2) proteins (Immune Technology). Measurements were made using a Bio-Plex 200.
THP-1 Phagocytosis Assay
The THP-1 phagocytosis assay was performed in duplicate, using fluorescent neutravidin 
beads (Invitrogen) coupled to biotinylated rgp120MN, as previously described[30].
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Rapid Fluorometric ADCC antibody mediated NK activation assays
The modified rapid fluorescent ADCC (RFADCC) assay using isolated NK cells 
(RosetteSep) from healthy donors as effector cells with CEM-NKr T cells pulsed with 
rgp120MN at target cells was performed in duplicate as previously described[31].
NK activation assay
Ab-dependent NK cell degranulation and activation were assessed by measuring CD107a, 
IFN-γ and MIP-1b as previously described[31]. Briefly, rgp120MN-pulsed CEM-Nkr T cells 
were mixed with isolated primary NK cells from healthy donors at a ratio of 1:5 prior to 
addition of purified IgG, anti-CD107a-PE/Cy5, brefeldin A (Sigma) and Golgistop (BD 
Biosciences) for 5 hours at 37°C. Cells were then stained intracellularly with anti-IFN-γ-
APC and anti-MIP-1β-PE, fixed and analyzed using flow cytometry. All antibodies were 
purchased from BD Biosciences.
Antibody Dependent Cellular Viral Inhibition Assay (ADCVI)
ADCVI was used to measure the antiviral activity of purified Abs in triplicate, as previously 
described[32]. Healthy CD4+ T cells were infected at an MOI of 0.01 with JR-CSF. 4 days 
following co-incubation of the infected CD4+ T cells, Abs and healthy NK cells, supernatant 
was collected and the level of inhibition was quantified using TZM-bl cells. Each data point 
displayed represents the average ADCVI activity from a single Ab sample tested in three 
different effector/target donors.
LASSO/PLS model for disease outcome
To predict disease outcome, Ab effector functions and IgG subclasses across Env 
specificities were used as inputs, and “control versus non-control” was used as the binary 
output. As consensus hierarchical clustering using Euclidean distances revealed that the 
early (week 4 and 12) and late time-points (week 24 and 48) clustered together, time-points 
were collapsed by averaging across them. For each feature, Z-scores at the “early” and “late” 
time-points were computed. These were then used as inputs to the model.
A stringent variable selection was initially performed, using the least absolute shrinkage and 
selection operation (LASSO)[33] to further prevent overfitting of the data. These features 
were then used in a partial least squares discriminant analysis, as previously described[34]. 
The accuracy of each of the models was assessed using a 5-fold cross-validation setup i.e. 
subjects were split into five subsets such that four subsets were used for training and the fifth 
was used in the test set, repeated 5 times with each subset serving as the test set once. This 
entire procedure constitutes one “5-fold cross-validation run”. For each model, the median 
classification accuracy across 50 independent cross-validation runs was measured, providing 
a robust measure of statistical significance.
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Results
Temporal variation of Ab-related features allows accurate separation of spontaneous 
controllers and chronic progressors during acute infection
Plasma samples from nine controller subjects and ten progressor subjects at weeks 4, 12, 24 
and 48 post-infection were evaluated. None of these subjects were carriers of HLA class I 
alleles previously associated with delayed progression of disease or improved viral 
control[19]. No striking univariate trends were observed for either Ab effector functions or 
IgG subclass levels across the two groups (Figs 1A and 1B). This suggests that individual 
Ab measurements have limited power in predicting viral control during acute infection.
We next sought to determine whether multivariate differences in Ab-related features may 
exist within the two groups of subjects. Hierarchical clustering of all time-points pointed to 
“early” (week 4 and week 12) and “late” (week 24 and week 48) Ab profiles. We built a 
LASSO/PLS model on averages across the early and late time-points, enabling the 
incorporation of both the temporal and cohort-specific variation into our modeling approach. 
Interestingly, the model was able to achieve reproducible and significant separation (median 
classification accuracy of 0.74) between the controllers and progressors (Fig. 1C and D), 
highlighting the existence of multivariate humoral profile differences among subjects that 
progress compared to those who control disease spontaneously.
LASSO uses stringent variable selection to prevent overfitting; only 3 variables were 
selected by the model to separate controllers and progressors (Fig. 1E). Interestingly, the top 
variables included subclass selection profile differences, highlighting qualitative differences 
in antibody Fc-profiles that diverge with disease progression. Specifically, in terms of the 
absolute amount of Ab present, early gp120-specific IgG2 Abs were enriched among the 
controllers, whereas later gp140-specific IgG2 and gp41-specific IgG3 responses were 
elevated within the progressors (Fig. 1E). Interestingly, in addition to explaining differences 
between controllers and progressors, these responses also captured within-group variation – 
LV1 and LV2 of the model primarily capture inter- and intra-group variation respectively 
(Fig. 1C). Thus, while previous studies highlighted the predictive value of HIV-specific 
IgG3 levels in the diagnosis of acute HIV infection[14], the data presented here highlight the 
additional importance of measuring IgG2 responses as these may allow for enhanced 
discrimination between subjects who will progress or control disease following acute HIV 
infection.
Lack of disease control is associated with gain of Env-specific IgG2 Abs at the expense of 
Env-specific IgG3 Abs during acute infection
To further probe the underlying changes in HIV-specific Ab subclass differences among the 
groups, we next sought to examine all Env-specific subclass levels and Ab functional 
changes in greater depth. We focused on Ab-related features from the earliest (week 4) and 
latest (week 48) time-points given the similar behavior of Ab profiles early and later in the 
first year of HIV infection. Env-specific IgG1 Abs either remained stable or increased in 
both cohorts (Fig. 2A and 2B). gp41-specific IgG3 declined in both the controller and 
progressor cohorts (Fig. 2A and 2B), in agreement with earlier data[14]. However, the extent 
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of decline (i.e., the amount lost relative to what was initially present) was higher for 
progressors than for controllers (Figs. 2A and 2B). Further, there was a marked decrease in 
gp120- and gp140-specific IgG3 Abs between the early and late time-points for the 
progressor group, but not for the controller group (Figs. 2A and 2B). This decrease was 
coupled with an increase in all Env-specific IgG2 Abs in progressors over time (Fig. 2B). In 
contrast, gp41- and gp140-specific IgG2 Abs remained stable in controllers over time, and 
there was only a slight increase in gp120-specific IgG2 Abs (Fig. 2A). Collectively, these 
data suggest that maintaining high-affinity FcγR binding IgGs such as IgG3, and not gaining 
lower-affinity IgG Abs, such as IgG2, are associated with controlled viremia.
Although Ab-effector functions were not selected by the LASSO/PLS model in 
differentiating between the two groups (Figs. 1C to 1E), likely due to the fact that they 
correlate with changes in subclass levels and fluctuated with time. Specifically, while a 
moderate decline in ADCVI was observed in progressors, ADCVI levels remained stable in 
controllers between weeks 4 and 48 post-infection (Figs. 2C and 2D). This is consistent with 
the relative increase of less polyfunctional Env-specific IgG2 Abs and the loss of more 
polyfunctional Env-specific IgG3 Abs in the progressor group.
To test whether changes in ADCVI could potentially be driven by specific IgG subclasses, 
we examined linear and non-linear relationships between ADCVI and all IgG subclass 
levels. Due to the small sample size, strong linear relationships (Spearman correlations) 
between ADCVI and subclass levels were not observed. However, we speculated that the 
link could be more complex and non-linear. To capture such relationships, we computed the 
maximal information coefficient (MIC)[35] between ADCVI and all IgG subclass levels. 
MIC is a non-parametric maximal information based statistic that can quantity a wide range 
of relationships. We found that, at early time points, there is a very strong link between 
ADCVI and gp120 IgG3 at week 4 (MIC = 0.51, highest MIC across all subclasses). 
However, this relationship is lost at week 48. This is consistent with our hypothesis that at 
early time points, both controllers and progressors have high ADCVI, potentially linked to 
high levels of IgG3 antibodies. However, the loss of IgG3 over time in progressors may 
result in a loss of functional antibody functional coordination, as previously described[26].
To further examine whether ADCVI is related to relative abundances of the different 
subclasses, and not just the raw abundance of IgG3, we computed the MIC between ADCVI 
and all IgG subclass fractions. We found moderately strong non-linear relationships 
(0.3<=MIC<=0.5) between ADCVI and IgG2, IgG3 and IgG4 both at week 4 and week 48. 
This suggests that ADCVI could be linked not only to the raw abundance of IgG3, but also 
to the relative levels of the different subclasses, as the loss of one subclass is usually tied to 
the gain of another.
Overall, our data show that different Ab-related profiles emerge with time during acute 
infection and that divergence in relative abundance of both IgG2 and IgG3 Abs tracks with 
changes in ADCVI and serves as a marker of disease progression.
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Discussion
There is a growing appreciation for a potential role of non-neutralizing Abs in the control of 
HIV infection[15–17, 36]. Moreover, recent studies have pointed to a role for qualitatively 
superior IgG3 and IgG1 Abs in driving polyfunctional responses in spontaneous controllers, 
while comparatively less functional IgG2 and IgG4 Ab responses have been shown to be 
more prevalent in viremic subjects[26]. Here, we evaluated whether differential Ab profiles 
emerge in acute infection and potentially contribute to or predict antiviral control. While 
univariate differences failed to define disease progression profiles, multivariate approaches 
that capture the interplay between Ab types and function point to significant temporal 
changes in Env-specific Ab profiles that predict disease outcome. Collectively, this analysis 
points to the potential role for the preservation of specific Ab profiles with enhanced viral 
control.
The rate of HIV-specific IgG3 Ab decline during acute infection has been proposed as a 
biomarker of the time from HIV infection[14]. While similar decay in HIV-specific IgG3 Abs 
was observed here, this loss selectively occurred in subjects who progressed to chronic 
disease, suggesting that the preservation of IgG3 Abs may be a key predictor of spontaneous 
control of HIV infection. It is also possible that HIV-specific IgG3 Abs qualitatively differ 
between the two cohorts, perhaps by targeting different viral epitopes, with higher affinity, 
or via differential antibody glycosylation in the controllers. Previous data has shown that 
non-neutralizing IgG3 Abs were an immune correlate of protection in the RV144 vaccine 
trial, tracking with increased antibody polyfunctionality[31], further suggesting that the 
generation and maintenance of IgG3 Abs could be vital to both prevention of infection, as 
well as to antiviral control upon infection[37].
However, the induction of IgG3 alone may not be sufficient to predict enhanced function. 
The data presented here suggest that in addition to the IgG3 Ab signature, Env-specific IgG2 
Abs were also significant contributors to separation between the controller and progressor 
groups in our model. Increased antigen load, changes in immune cell activation and 
disrupted lymphoid architecture along with enhanced immune activation reflected by 
elevated levels of inflammatory cytokines such as BAFF[13],which is known to impact class 
switch[38, 39], could be driving downstream class-switch recombination in progressors. 
Interestingly, enhanced immune activation correlates with a decline in ADCVI during early 
infection and this further correlates with a decline in IgG3 Abs[13]. Here, ADCVI – while 
initially comparable between the controller and progressor cohorts – uniquely displayed a 
downward trend among progressors, potentially linked to this altered Ab subclass profile. 
While this shift in ADCVI could reflect a change in Ab neutralization, the overall effect 
would not be great, as limited neutralization has previously been reported in this 
cohort[1, 40]. Neutralization activity would likely increase over the course of infection as B 
cells undergo affinity maturation. The retention of IgG3 and ADCVI in the controller group 
could be a biomarker of a more efficacious antiviral response and less immune activation or 
may be directly linked to enhanced reservoir control, as has been previously suggested[26]. 
Thus, it seems likely that the selective loss of Env-specific IgG3 Abs combined with gains in 
less polyfunctional Env-specific IgG2 Abs may relate to the decrease in ADCVI in the 
progressor cohort.
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Here we show that objective and comprehensive antibody profiling along with multivariate 
analyses provides a powerful opportunity to define humoral immune profiles that track with 
distinct clinical outcomes following acute HIV infection. Specifically, we observed that the 
combination of Ab subclass profiles, rather than any single Ab feature, was key to predicting 
whether a subject is a controller or progressor. While it is still uncertain whether Abs 
contribute directly to the antiviral response that results in the “controller” phenotype, 
vaccines that elicit ADCC inducing antibodies in NHPs drive enhanced antiviral control in 
an analogous manner[41]. Further analyses of fine epitope specificities on the viral envelope 
of both IgG3 and IgG2 Abs during acute infection, along with additional Ab-dependent 
effector functional measurements, may shed light on the specific targets and mechanisms 
that contribute to antiviral control. They could also point to new sites of viral vulnerability 
for antibodies that could help guide the development of more efficacious vaccines and 
therapeutics.
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Figure 1. Changes in HIV-specific IgG subclasses between early and late acute infection 
effectively and rigorously differentiate between progressors and controllers
A – The confetti plot depicts the Ab effector functions (Z-scores) in progressors (CROs) and 
controllers (CTRs).
B – The confetti plot depicts gp120-, gp140- and gp41-specific IgG subclass levels (Z-
scores) in progressors (CROs) and controllers (CTRs).
C – The LASSO/PLS model illustrates separation between progressors and controller Ab 
profiles. Ellipses correspond to estimated 75% confidence intervals.
D – The violin plots compare classification accuracy for the LASSO/PLS model for 
separating progressors and controllers, from 100 rounds of 5-fold cross-validation using 
actual, permuted and randomly selected (size-matched) features. Significance was measured 
using a U/Wilcoxon ranked test.
E – The Variable Importance in the Projection (VIP) plot corresponding to the LASSO/PLS 
model illustrates the relative importance (longer bar = more important) of the selected 
features. Colors correspond to the group (progressors/controllers) the feature is higher in.
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Figure 2. Progressors lose HIV-specific IgG3 Abs and gain HIV-specific IgG2 Abs during acute 
infection
A – The radar plot illustrates antigen-specific IgG subclass levels in controllers at weeks 4 
(dotted line) and 48 (solid line) respectively.
B – The radar plot illustrates antigen-specific IgG subclass levels in progressors at weeks 4 
(dotted line) and 48 (solid line) respectively.
C – The radar plot illustrates different Ab-dependent effector functions in controllers at 
weeks 4 (dotted line) and 48 (solid line) respectively.
D – The radar plot illustrates different Ab-dependent effector functions in progressors at 
weeks 4 (dotted line) and 48 (solid line) respectively.
For all radar plots, each axis is on a scale corresponding to the IgG subclass level/function 
under consideration. The outermost point corresponds to the highest value of the feature 
being plotted along that axis.
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